Tudor Investment Corp’s Blueprint Medicines BPMC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-468,623
Closed -$60.1M 3381
2025
Q2
$60.1M Buy
468,623
+446,612
+2,029% +$46.4M 0.13% 101
2025
Q1
$1.95M Buy
22,011
+13,911
+172% +$1.36M 0.01% 1364
2024
Q4
$706K Buy
+8,100
New +$742K ﹤0.01% 1985
2023
Q2
Sell
-9,663
Closed -$435K 2458
2023
Q1
$435K Buy
+9,663
New +$435K 0.01% 1702
2022
Q4
Sell
-28,444
Closed -$1.87M 2403
2022
Q3
$1.87M Buy
28,444
+9,639
+51% +$619K 0.04% 568
2022
Q2
$950K Buy
18,805
+8,700
+86% +$510K 0.02% 920
2022
Q1
$646K Buy
10,105
+2,253
+29% +$162K 0.02% 1133
2021
Q4
$841K Sell
7,852
-3,108
-28% -$325K 0.01% 1115
2021
Q3
$1.13M Sell
10,960
-70,299
-87% -$6.55M 0.02% 1075
2021
Q2
$7.15M Buy
+81,259
New +$7.45M 0.14% 127
2018
Q1
Sell
-10,582
Closed -$798K 1012
2017
Q4
$798K Buy
10,582
+6,716
+174% +$473K 0.02% 426
2017
Q3
$269K Sell
3,866
-1,751
-31% -$93.6K 0.01% 865
2017
Q2
$285K Sell
5,617
-40,344
-88% -$1.71M 0.01% 775
2017
Q1
$1.84M Buy
45,961
+3,402
+8% +$122K 0.06% 209
2016
Q4
$1.19M Buy
42,559
+33,156
+353% +$999K 0.03% 300
2016
Q3
$279K Buy
+9,403
New +$234K 0.01% 1066

Other funds holding BPMC

Tudor Investment Corp's BPMC Position: Q3 2025 in Review

Tudor Investment Corp sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 468,623 shares — an estimated $60.1M sold.

Tudor Investment Corp first reported a position in BPMC in Q3 2016 and held it in 16 quarters. The position peaked at $60.1M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Tudor Investment Corp reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Tudor Investment Corp sold 468,623 Blueprint Medicines shares in Q3 2025, an estimated $60.1M.
  • Tudor Investment Corp first reported a position in Blueprint Medicines in Q3 2016 and held it in 16 quarters.
  • Tudor Investment Corp's Blueprint Medicines position peaked at $60.1M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Tudor Investment Corp's 13F filing for Q3 2025, filed 14 Nov 2025.